The pharmaceutical industry thrives on innovative products and clinically differentiated medicines that can create real value. Innovation has the greatest impact on a pharmaceutical company’s long-term success, yet pressure to reduce drug prices from both government and consumers may force drug companies to seek alternative
revenue streams. The pharmaceutical industry is in a constant state of flux, and it has never been more important for industry insiders to identify trends and anticipate outcomes.
The obstacles to success in the industry over the next ten years are numerous and complicated. 2015: Strategic Considerations for the U.S. Pharmaceutical Industry maps out the competitive, scientific, and regulatory hurdles ahead, and offers insightful and creative business strategies to navigate through the challenges, capitalize on the opportunities, and adapt to change.This report offers a thorough analysis of current trends and issues that are challenging high-level decision making, including the following:
- The main issues that companies face as a result of globalization.
- The need to align products and markets, and differentiate products.
- Key issues in forming development partnerships.
- Convergence strategies—finding new combinations of formerly distinct market segments for a company’s pharmaceuticals, therapeutic devices, and diagnostic processes or equipment.
- Outstanding needs in new product development & commercialization.
- Managing the regulatory environment and drug approval process.
2015: Strategic Considerations for
the US Pharmaceutical Industry builds
on this analysis by constructing 4 bold scenarios based on the
interaction between the fundamental drivers of change —customized
therapeutics versus blockbuster drugs, and free market versus price
control. Using these two drivers and their variables, the report
details developments in the following four areas:
- Market and regulatory
The scenarios are based on direct input from industry insiders through in-depth interviews as well as extensive secondary research of the US market. This analysis provides insight into the issues that will shape the industry and prompts managers to begin preparing for long-term changes.
About the Author
Dr. DiFelice received BS and MS degrees in chemistry from the
Rochester Institute of Technology (RIT) and earned Ph.D. in chemistry
with honors from Virginia Tech. He was a Post-Doctoral Fellow
at RIT and earned his MBA with honors from Kenan-Flagler Business
School (UNC-Chapel Hill). He is the Founder and President of
Alpha V, Inc., a company that is commercializing a long-lasting
micro-battery (potentially 100 year lifetime) to power implantable
devices and wireless sensors. Dr. DiFelice also consults within
the venture capital industry on emerging biotechnology companies,
and advises both large and small companies on corporate strategy
issues in both the pharmaceutical and energy sectors.